The development of antiretroviral therapy for the prevention and treatment of HIV infection
has been marked by a series of remarkable successes. However, the efforts to develop a …

The newest class of antiretrovirals for all persons living with HIV are the integrase strand
transfer inhibitors (INSTIs). Since 2007, five INSTIs have been introduced: raltegravir …

Importance Recent advances in treatment and prevention of HIV warrant updated
recommendations to guide optimal practice. Objective Based on a critical evaluation of new …

Background Safe and effective long-acting injectable agents for preexposure prophylaxis
(PrEP) for human immunodeficiency virus (HIV) infection are needed to increase the options …

The long-acting antiretroviral cabotegravir and rilpivirine combination has just received FDA,
EMA and Health Canada approval. This novel drug delivery approach is about to …

Abstract Background The HIV Prevention Trials Network (HPTN) 083 trial demonstrated that
long-acting cabotegravir (CAB-LA) was more effective than tenofovir disoproxil fumarate …

Combined antiretroviral treatments have significantly improved the morbidity and mortality
related to HIV infection, thus transforming HIV infection into a chronic disease; however, the …

Intramuscular injection of long-acting cabotegravir and rilpivirine is a novel, long-acting
antiretroviral therapy (ART) combination approved for use as a fully suppressive regimen for …

Abstract Background HIV Prevention Trials Network 084 demonstrated that long-acting
injectable cabotegravir (CAB) was superior to daily oral tenofovir (TFV) disoproxil fumarate …

Cabotegravir+ rilpivirine administered via intramuscular gluteal injections is the first
complete long-acting (LA) regimen approved for maintaining HIV-1 virologic suppression …